STOCK TITAN

SELLAS Life Sciences CEO sells 26,606 shares for taxes

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

SELLAS Life Sciences Group, Inc. (SLS) President and CEO Angelos M. Stergiou reported a sale of 26,606 shares at $19.1780 per share on November 18, 2026. The sale satisfied tax withholding when previously granted performance-based restricted stock units vested after the primary endpoint was met in the Phase 3 REGAL study. The company’s equity plans require this “sell to cover” mechanism; the footnote says the sale was not discretionary. Stergiou directly held 1,734,896 shares after the transaction.

Insider Stergiou Angelos M.
Role President and CEO
Sold 26,606 shs ($510K)
Share of Position Sold 1.5%
Type Security Shares Price Value
Sale Common Stock F1 26,606 $19.178 $510K
Holdings After Transaction: Common Stock — 1,734,896 shares (Direct)
Holdings Before and After: Common Stock, 1,761,502 to 1,734,896 shares (Direct)
Footnotes (1)
  1. F1. Represents shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the performance based vesting of certain previously granted restricted stock units upon meeting the primary endpoint in the Issuer's Phase 3 REGAL study. These sales are mandated as part of the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Shares sold 26,606 shares November 18, 2026; tax-withholding sale
Sale price $19.1780 per share November 18, 2026
Direct shares held after transaction 1,734,896 shares Angelos M. Stergiou
restricted stock units financial
"vesting of certain previously granted restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sell to cover financial
"funded by a “sell to cover” transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
tax withholding obligation financial
"satisfy the Reporting Person’s tax withholding obligation"
primary endpoint medical
"upon meeting the primary endpoint in the Issuer’s Phase 3 REGAL study"
The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SLS shares did CEO Angelos M. Stergiou sell and at what price?

Angelos M. Stergiou sold 26,606 shares at $19.1780 per share on November 18, 2026. The shares were sold to satisfy tax withholding tied to vesting of previously granted performance-based restricted stock units.

Why did Angelos M. Stergiou sell SLS shares?

The transaction was a required “sell to cover” for tax withholding connected to vesting of previously granted performance-based restricted stock units after the primary endpoint was met in the Phase 3 REGAL study; the footnote says it was not a discretionary trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stergiou Angelos M.

(Last)(First)(Middle)
C/O SELLAS LIFE SCIENCES GROUP, INC.
7 TIMES SQUARE, SUITE 2503

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
SELLAS Life Sciences Group, Inc. [ SLS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/18/2026S26,606(1)D$19.1781,734,896D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the performance based vesting of certain previously granted restricted stock units upon meeting the primary endpoint in the Issuer's Phase 3 REGAL study. These sales are mandated as part of the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
/s/ Kostantinos Skordalos, Power of Attorney For: Angelos M. Stergiou11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading